Tcr2 Therapeutics Inc (NASDAQ:TCRR) has received a consensus recommendation of “Buy” from the nine research firms that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $26.33.

Several research firms have commented on TCRR. Zacks Investment Research downgraded shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, November 16th. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of Tcr2 Therapeutics in a research note on Wednesday, November 13th. Finally, ValuEngine cut Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 27th.

Shares of TCRR opened at $16.86 on Friday. The firm has a 50-day moving average of $14.98 and a 200-day moving average of $15.27. Tcr2 Therapeutics has a one year low of $10.04 and a one year high of $25.47. The company has a market cap of $407.38 million and a PE ratio of -0.17.

Tcr2 Therapeutics (NASDAQ:TCRR) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.03). As a group, analysts expect that Tcr2 Therapeutics will post -5.1 earnings per share for the current year.

In other news, major shareholder Morana Jovan-Embiricos sold 416,321 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $17.92, for a total transaction of $7,460,472.32. Over the last ninety days, insiders sold 484,313 shares of company stock valued at $8,609,469. Insiders own 39.07% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TCRR. BlackRock Inc. acquired a new position in Tcr2 Therapeutics during the second quarter worth $1,511,000. Rhumbline Advisers bought a new position in Tcr2 Therapeutics in the 3rd quarter valued at about $162,000. Vanguard Group Inc. acquired a new position in Tcr2 Therapeutics during the 2nd quarter valued at about $1,070,000. Parametric Portfolio Associates LLC boosted its stake in Tcr2 Therapeutics by 23.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock valued at $501,000 after purchasing an additional 6,672 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new position in Tcr2 Therapeutics during the 2nd quarter valued at about $349,000. Hedge funds and other institutional investors own 42.15% of the company’s stock.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

See Also: What is the CAC 40 Index

Analyst Recommendations for Tcr2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.